Quetiapine treatment of rapid-cycling bipolar disorder: An open prospective study

Ghaemi, S. Nassir; Goldberg, Joel; Ko, James Y.; Garno, Jessica L.

doi:10.1016/s0924-977x(01)80287-x

Cited by 12 publications

(12 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Preliminary studies suggest that quetiapine is effective in the treatment of mixed mania 32 and rapid cycling 33,34 . However, these subpopulations were excluded by the protocol in the present analysis.…”

Section: Safety and Tolerabilitymentioning

confidence: 99%

Quetiapine monotherapy for mania associated with bipolar disorder: combined analysis of two international, double-blind, randomised, placebo-controlled studies

Vieta

Mullen

Brecher

et al. 2005

Current Medical Research and Opinion

109

View full text Add to dashboard Cite

show abstract

Section: Safety and Tolerabilitymentioning

confidence: 99%

Quetiapine monotherapy for mania associated with bipolar disorder: combined analysis of two international, double-blind, randomised, placebo-controlled studies

Vieta

Mullen

Brecher

et al. 2005

Current Medical Research and Opinion

109

View full text Add to dashboard Cite

show abstract

“…Also, 8 of 12 bipolar patients with cocaine dependence showed significant improvement of mood and drastically reduced the amount of money spent on cocaine after 12 weeks of quetiapine treatment (Brown et al 2001 , Table 1). Overall, based on the uncontrolled studies that reported the number of responders Dunayevich 2001;Ghaemi et al 2001), the mean antimanic response to quetiapine in bipolar patients was 67% (35 of 52 patients), at a mean dose of 217 mg/day (Table 6).…”

Section: Quetiapinementioning

confidence: 99%

Atypical antipsychotics and mood stabilization in bipolar disorder

2003

View full text Add to dashboard Cite

The available literature on the use of atypical antipsychotics for the treatment of bipolar disorder was reviewed. All uncontrolled and controlled reports were identified through a comprehensive Medline search. Based on the available evidence, olanzapine was found to be the most appropriate atypical antipsychotic agent utilized for the treatment of manic bipolar patients, although there is also preliminary data suggesting the efficacy of risperidone and clozapine. The preliminary data evaluating the efficacy of quetiapine and ziprasidone in bipolar disorder are still very limited. Double-blind controlled studies with atypical antipsychotics in the long-term treatment of bipolar disorder are still largely not available, but will be critical to determine the effectiveness of these agents in the maintenance treatment of bipolar disorder. There are recent uncontrolled suggestions that olanzapine may have beneficial effects in depressed bipolar patients, which deserve further investigation in controlled studies. In conclusion, atypical antipsychotics, due to lower potential for neurotoxicity and preliminary evidence suggesting better efficacy than typical antipsychotics, are increasingly having a more prominent role in the pharmacological management of bipolar patients. Nonetheless, until there is systematic data from long-term controlled follow-up studies on the comparative efficacy of these agents with mood stabilizers, atypical antipsychotics should be cautiously utilized, and preferably in combination with a mood stabilizer for the maintenance phase of treatment.

show abstract

“…In an open-label study Ghaemi et al (2002) also found that quetiapine was effective and well tolerated in rapid-cycling bipolar disorder. Mania and depression scores decreased significantly from baseline in the 16 patients with available data.…”

Section: Quetiapine In the Treatment Of Rapid-cycling Bipolar Disordermentioning

confidence: 89%

“…In large randomized trials, as well as in smaller or open studies, significant and independent improvements in depression rating scores of patients with schizophrenia and bipolar mania had been detected Small et al, 1997;Emsley et al, 2000;Mullen et al, 2001;Sajatovic et al, 2001;Brown et al, 2002;DelBello et al, 2002;Ghaemi et al, 2002;Sajatovic et al, 2002;Baldassano et al, 2004;Vieta et al, 2005).…”

Section: Quetiapine In the Treatment Of Bipolar Depressionmentioning

confidence: 99%

Mood stabilization in the treatment of bipolar disorder: focus on quetiapine

Vieta

2005

Human Psychopharmacology

View full text Add to dashboard Cite

The use of at least one mood-stabilizing agent is common clinical practice in the treatment of bipolar disorder, regardless of the treatment setting or disease phase. However, a consensus definition of 'mood stabilizer' remains to be established. A mood stabilizer has been operationally described as an agent that is useful in at least one phase of bipolar disorder while not worsening any other phase of the illness. More stringent definitions have been proposed, and it can be argued that a clinically effective mood stabilizer would have efficacy in a broad range of affective, psychotic, behavioral and cognitive domains in all phases of bipolar disorder and would be well tolerated across a range of doses for sustained periods. Clinically effective mood stabilizers should treat mania and depression, while preventing recurrence and improving quality of life. Effective treatment should not precipitate mania, depression, or rapid cycling, and should minimize the burden of treatment-emergent side effects. Data from clinical studies of quetiapine are reviewed in context with the literature discussing traditional and emerging mood stabilizers. Using a liberal definition, the evidence for quetiapine qualifies it as a bimodal mood stabilizer based on its demonstrated effectiveness in the treatment of bipolar mania and depression. Further data suggest that quetiapine has promise across all phases of bipolar disorder with the potential to meet even the most stringent definitions of a mood stabilizer.

show abstract

Quetiapine treatment of rapid-cycling bipolar disorder: An open prospective study

Cited by 12 publications

References 0 publications

Quetiapine monotherapy for mania associated with bipolar disorder: combined analysis of two international, double-blind, randomised, placebo-controlled studies

Quetiapine monotherapy for mania associated with bipolar disorder: combined analysis of two international, double-blind, randomised, placebo-controlled studies

Atypical antipsychotics and mood stabilization in bipolar disorder

Mood stabilization in the treatment of bipolar disorder: focus on quetiapine

Contact Info

Product

Resources

About